MaxCyte, Inc.
9713 Key West Ave., Suite 400
Rockville
Maryland
20850
United States
Tel: 1-301-944-1700
Fax: 1-301-944-1703
Website: http://www.maxcyte.com/
Email: careers@maxcyte.com
About MaxCyte, Inc.
We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.
This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides unparalleled consistency and minimal cell disturbance – facilitating rapid, large-scale, clinical- and commercial-grade cell-engineering in a non-viral system and with low-toxicity concerns. Our cell-engineering platform is FDA-cleared, providing our customers and partners with an established regulatory path to commercialize cell-based medicines.
We are also developing novel CARMA cellular therapies for our own pipeline with our first drug candidate in a Phase I clinical trial. CARMA is MaxCyte’s novel proprietary technology for development of human mRNA-based cellular therapies to treat a broad range of diseases.
Stock Exchange: Alternative Investment Market
Stock Symbol: MXCT
At MaxCyte, we take a collaborative partnering approach with our clients with the goal of rapidly driving our partners’ development efforts forward through to commercial use, more cost-effectively and with lowered risk. We have developed and commercialized MaxCyte Scalable Transfection Systems for high-performance delivery of biomolecules using Flow Electroporation ® Technology, a proprietary cell-engineering technology designed to meet the stringent demands of clinical use – namely, the ability to safely and reproducibly modify primary human cells with high efficiency, low cytotoxicity, and at the scale required to treat patients.
186 articles with MaxCyte, Inc.
-
MaxCyte Appoints Dr. Claudio Dansky Ullmann as Chief Medical Officer
4/25/2018
MaxCyte announced today that it has appointed Claudio Dansky Ullmann, MD, a 25+-year expert in clinical oncology and pharmaceutical research, as its Chief Medical Officer (CMO).
-
Dr. Richard Douglas Joins MaxCyte Board
2/13/2018
Dr. Douglas formerly served as the Senior Vice President of Corporate Development and Corporate Officer at Genzyme Corporation from 1989 until Genzyme was acquired by Sanofi in 2011.
-
MaxCyte Appoints Executive Vice President Of Global Marketing
8/14/2017
-
MaxCyte And NIAID To Collaborate On Research For Ultra-Rare Disease Therapy
6/6/2017
-
CRISPR And Casebia Therapeutics Announce Commercial License Agreement With MaxCyte, Inc.
3/14/2017
-
MaxCyte, Inc. Release: Biopharma Trading Update
1/24/2017
-
MaxCyte, Inc. Release: Company, NIH NIAID Study Published In Science Translational Medicine Demonstrates CRISPR-Cas9 Repair Of X-Linked Chronic Granulomatous Disease (CGD) Gene
1/12/2017
-
MaxCyte, Inc. Announces Strategic Immuno-Oncology Collaboration To Advance New Generation Of CAR-Based Cell Therapies
12/21/2016
-
MaxCyte, Inc. Appoints Executive Vice President, Business And Strategic Development
11/2/2016
-
MaxCyte, Inc. Announces A CRADA With US Army Medical Research Institute Of Infectious Diseases For An Exploratory Research Collaboration On Rapid Response Medical Countermeasures
5/17/2016
-
MaxCyte, Inc. To Present Gene Editing Results At The American Society Of Gene And Cell Therapy Annual Meeting
4/21/2016
-
MaxCyte, Inc. To Present Data On Expression And Functionality Of Bispecific Antibodies Produced Via Transient Transfection
3/10/2016
-
MaxCyte, Inc. Partner To Present Data At The Inaugural Bioprocess International West Conference
3/10/2016
-
MaxCyte, Inc. Partners To Present Data At Annual Biophysical Society Meeting
2/24/2016
-
MaxCyte, Inc. To Present At Biotech Showcase 2016
1/7/2016
-
MaxCyte, Inc. And Partners To Present Data At PEGS Europe
11/2/2015
-
MaxCyte, Inc. To Present At 2015 Bioprocess International Conference
10/26/2015
-
MaxCyte, Inc. Appoints Spinco Biotech Pvt Ltd. As Distributor In India For The MaxCyte STX And MaxCyte VLX
10/20/2015
-
MaxCyte, Inc.To Present Novel Approach To Car-T For Treatment Of Solid Tumors At Biochemical Society In London
10/13/2015
-
MaxCyte, Inc. To Present At 2015 Immuno-Oncology Conference
9/30/2015